^
    3d
    A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults (clinicaltrials.gov)
    P1, N=24, Completed, BeOne Medicines | Active, not recruiting --> Completed
    Trial completion
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)
    3d
    MAZ-01: Zanubritnib and anti-MAG neuropathy (2025-523091-23-00)
    P1/2, N=50, Recruiting, Azienda Ospedaliera di Padova | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Brukinsa (zanubrutinib)
    9d
    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) (clinicaltrials.gov)
    P2, N=230, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
    10d
    CA-4948-203: A Ph2 Study of Emavusertib + an Approved BTKi in Patients with CLL and Other B-cell Malignancies (2025-523600-68-00)
    P1/2, N=40, Not yet recruiting, Curis Inc.
    New P1/2 trial
    |
    clonoSEQ
    |
    Brukinsa (zanubrutinib) • emavusertib (CA-4948)
    11d
    VIS: Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL (clinicaltrials.gov)
    P2, N=78, Active, not recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | Recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
    12d
    Efficacy and safety analysis of BTK inhibitors combined with R-CHOP regimen in newly diagnosed double-expressor diffuse large B-cell lymphoma (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    Among them, 35 patients received BTKi (zanubrutinib, orelabrutinib, acalabrutinib) combined with R-CHOP (BTKi + R-CHOP group) , and 60 received R-CHOP regimen alone (R-CHOP group) . Grade ≥ 3 adverse events primarily included neutropenia (28.6% ) and pulmonary infection (14.3% ) ; no fatal bleeding or cardiovascular events occurred. BTKi combined with R-CHOP significantly improved response rates and survival in patients with DE-DLBCL, with manageable safety.
    Retrospective data • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Inokai (orelabrutinib)
    19d
    SEQUOIA: A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (clinicaltrials.gov)
    P3, N=590, Active, not recruiting, BeiGene | Trial completion date: Sep 2026 --> Oct 2027
    Trial completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Brukinsa (zanubrutinib) • bendamustine
    21d
    Efficacy and safety of zanubrutinib combined with age-adapted bendamustine and rituximab followed by zanubrutinib maintenance therapy in elderly patients with mantle cell lymphoma: a retrospective analysis. (PubMed, Leuk Lymphoma)
    CD4 + T cell and NK cell counts declined to nadir post-induction but recovered by 12 months. Zanubrutinib combined with age-adapted bendamustine and rituximab, followed by zanubrutinib maintenance, is an active and feasible regimen for elderly patients with MCL, offering a potential treatment option in clinical practice.
    Retrospective data • Journal
    |
    CD4 (CD4 Molecule)
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib) • bendamustine
    22d
    HOVON169CAD: Zanubrutinib in Primary Cold Agglutinin Disease (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Stichting Hemato-Oncologie voor Volwassenen Nederland | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2027 --> Feb 2026
    Enrollment closed • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Brukinsa (zanubrutinib)
    25d
    A case report of lymphoplasmacytic lymphoma with spherocytosis. (PubMed, Open Life Sci)
    The patient's condition stabilized following targeted therapy with zanubrutinib and rituximab (ZR regimen). This case underscores the complexity of diagnosing dual hematological anomalies, highlights the importance of multidisciplinary collaboration, and seeks to explore the potential pathophysiological link between LPL and spherocytosis, offering a reference for diagnosis and treatment in similar clinical scenarios.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib)
    25d
    Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas (clinicaltrials.gov)
    P2, N=15, Recruiting, Baptist Health South Florida | Trial completion date: Feb 2031 --> Feb 2033 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    pemetrexed • Brukinsa (zanubrutinib)
    1m
    BruVenG: Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting
    Enrollment closed • Minimal residual disease
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)